A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT05042375 · UNKNOWN
Trial details
- NCT number
- NCT05042375
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-08
- Primary completion
- 2023-12-31
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.